Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for Puma Biotechnology (PBYI) over the last 4 years, with Dec 2024 value amounting to $121,000.

  • Puma Biotechnology's Other Non-Current Liabilities changed negligibly% to $121,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $121,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $121,000 for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q4 2024, Puma Biotechnology's Other Non-Current Liabilities stood at $121,000, which was down 0.00% from $121,000 recorded in Q3 2024.
  • In the past 5 years, Puma Biotechnology's Other Non-Current Liabilities ranged from a high of $26.0 million in Q4 2020 and a low of $37,000 during Q2 2022.
  • In the last 3 years, Puma Biotechnology's Other Non-Current Liabilities had a median value of $121,000 in 2024 and averaged $2.6 million.
  • Per our database at Business Quant, Puma Biotechnology's Other Non-Current Liabilities soared by 20,816.22% in 2023 and then plummeted by 98.44% in 2024.
  • Puma Biotechnology's Other Non-Current Liabilities (Quarterly) stood at $26.0 million in 2020, then tumbled by 96.48% to $915,000 in 2021, then skyrocketed by 707.76% to $7.4 million in 2022, then crashed by 98.36% to $121,000 in 2023, then remained steady at $121,000 in 2024.
  • Its Other Non-Current Liabilities stands at $121,000 for Q4 2024, versus $121,000 for Q3 2024 and $121,000 for Q2 2024.